HQL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
HQL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. abrdn Life Sciences Investors's annualized net income for the quarter that ended in Sep. 2024 was $70.08 Mil. abrdn Life Sciences Investors's average Total Stockholders Equity over the quarter that ended in Sep. 2024 was $450.38 Mil. Therefore, abrdn Life Sciences Investors's annualized ROE % for the quarter that ended in Sep. 2024 was 15.56%.
The historical rank and industry rank for abrdn Life Sciences Investors's ROE % or its related term are showing as below:
During the past 8 years, abrdn Life Sciences Investors's highest ROE % was 28.38%. The lowest was -22.71%. And the median was 9.46%.
The historical data trend for abrdn Life Sciences Investors's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
abrdn Life Sciences Investors Annual Data | |||||||||||||||||
Trend | Sep17 | Sep18 | Sep19 | Sep20 | Sep21 | Sep22 | Sep23 | Sep24 | |||||||||
ROE % | Get a 7-Day Free Trial | 28.38 | 12.82 | -22.71 | 5.59 | 19.80 |
abrdn Life Sciences Investors Semi-Annual Data | |||||||||||||||
Sep17 | Mar18 | Sep18 | Mar19 | Sep19 | Mar20 | Sep20 | Mar21 | Sep21 | Mar22 | Sep22 | Mar23 | Sep23 | Mar24 | Sep24 | |
ROE % | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
-13.59 | 16.48 | -5.55 | 23.85 | 15.56 |
For the Asset Management subindustry, abrdn Life Sciences Investors's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Asset Management industry and Financial Services sector, abrdn Life Sciences Investors's ROE % distribution charts can be found below:
* The bar in red indicates where abrdn Life Sciences Investors's ROE % falls into.
abrdn Life Sciences Investors's annualized ROE % for the fiscal year that ended in Sep. 2024 is calculated as
ROE % | = | Net Income (A: Sep. 2024 ) | / | ( (Total Stockholders Equity (A: Sep. 2023 ) | + | Total Stockholders Equity (A: Sep. 2024 )) | / count ) |
= | 85.296 | / | ( (401.934 | + | 459.695) | / 2 ) | |
= | 85.296 | / | 430.8145 | ||||
= | 19.80 % |
abrdn Life Sciences Investors's annualized ROE % for the quarter that ended in Sep. 2024 is calculated as
ROE % | = | Net Income (Q: Sep. 2024 ) | / | ( (Total Stockholders Equity (Q: Mar. 2024 ) | + | Total Stockholders Equity (Q: Sep. 2024 )) | / count ) |
= | 70.08 | / | ( (441.068 | + | 459.695) | / 2 ) | |
= | 70.08 | / | 450.3815 | ||||
= | 15.56 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Sep. 2024) net income data. ROE % is displayed in the 30-year financial page.
abrdn Life Sciences Investors (NYSE:HQL) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
ROE % | (Q: Sep. 2024 ) | ||||
= | Net Income | / | Total Stockholders Equity | ||
= | 70.08 | / | 450.3815 | ||
= | (Net Income / Revenue ) | * | (Revenue / Total Assets) | * | (Total Assets / Total Stockholders Equity) |
= | (70.08 / 71.71) | * | (71.71 / 451.265) | * | (451.265 / 450.3815) |
= | Net Margin % | * | Asset Turnover | * | Equity Multiplier |
= | 97.73 % | * | 0.1589 | * | 1.002 |
= | ROA % | * | Equity Multiplier | ||
= | 15.53 % | * | 1.002 | ||
= | 15.56 % |
With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.
The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:
ROE % | (Q: Sep. 2024 ) | ||||||
= | Net Income | / | Total Stockholders Equity | ||||
= | 70.08 | / | 450.3815 | ||||
= | (Net Income / Pre-Tax Income) | * | (Pre-Tax Income / Revenue) | * | (Revenue / Total Assets) | * | (Total Assets / Total Stockholders Equity) |
= | (70.08 / 70.08) | * | (70.08 / 71.71) | * | (71.71 / 451.265) | * | (451.265 / 450.3815) |
= | Tax Burden | * | Pretax Margin % | * | Asset Turnover | * | Equity Multiplier |
= | 1 | * | 97.73 % | * | 0.1589 | * | 1.002 |
= | 15.56 % |
Note: The net income data used here is two times the semi-annual (Sep. 2024) net income data. The Revenue data used here is two times the semi-annual (Sep. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income. * In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Thank you for viewing the detailed overview of abrdn Life Sciences Investors's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.
Bill Maher | director | 600 WEST BROADWAY, 30TH FL., SAN DIEGO CA 92101 |
Rose Dimartino | director | C/O ABRDN, 1900 MARKET STREET, PHILADELPHIA PA 19103 |
Kathleen Goetz | director | 1310 OAK VALLEY CIRCLE, POLK CITY IA 50226 |
Todd Reit | director | C/O ABERDEEN STANDARD INVESTMENTS, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103 |
James Joseph O'connor | other: Director of Adviser | C/O ABERDEEN STANDARD INVESTMENTS, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103 |
Marika Tooze | other: Director of Adviser | C/O ABRDN, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103 |
Aberdeen Standard Investments Inc. | other: Adviser | 1900 MARKET ST., 2ND FLOOR, PHILADELPHIA PA 19103 |
Jaclyn Marie Matsick | other: Director of Adviser | C/O ABRDN, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103 |
Lucia Sitar | officer: VP and Chief Legal Officer | 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103 |
Jennifer A Nichols | other: Director of Adviser | 1735 MARKET STREET, 37TH FLOOR, PHILADELPHIA PA 19103 |
Christian Pittard | officer: President | ONE BOW CHURCHYARD, LONDON X0 EC4M 9HH |
Megan Kennedy | officer: Secretary and Vice President | 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103 |
Sharon Ferrari | officer: Treasurer and CFO | 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103 |
Alan R Goodson | officer: Vice President | 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103 |
Joseph Andolina | officer: Chief Compliance Officer & VP | 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103 |
From GuruFocus
By Business Wire Business Wire • 02-16-2021
By Business Wire Business Wire • 11-12-2021
By GuruFocus News • 02-05-2025
By Business Wire • 09-29-2023
By Business Wire Business Wire • 01-06-2021
By Business Wire Business Wire • 12-30-2022
By Business Wire • 08-15-2023
By Business Wire • 06-30-2023
By Business Wire Business Wire • 03-31-2022
By Business Wire Business Wire • 05-15-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.